United States Drug Patent 4,704,282: Scope, Claims, Expiration and Transdermal Testosterone Patent Landscape

U.S. Patent No. 4,704,282 protected a thin, subsaturated matrix transdermal therapeutic system reinforced with drug-compatible fibers or fabric. Its central limitation required the reinforcing material to have a lower drug-flux capacity than the surrounding matrix:

[ D_r C_r < D_m C_o ]

The patent was assigned to ALZA Corporation and issued on November 3, 1987. Because it was governed by the pre-URAA 17-year patent term, the patent expired in 2004. It no longer creates an enforceable U.S. patent barrier for testosterone, progesterone, hydrocortisone, or other transdermal products.

Its commercial significance was historical. The claims cover the design architecture associated with scrotal testosterone patches, including ethylene-vinyl acetate, or EVA, matrices, reinforcing fibers, thin patch construction, low skin peel strength, and daily replacement for testosterone replacement therapy.

What does U.S. Patent 4,704,282 protect?

The patent protects a reinforced, adhesive matrix patch engineered to avoid the release-rate reduction that could otherwise result from embedding fabric or fibers in a drug-containing polymer.

The core elements are:

Claim element	Scope
Active-agent matrix	Matrix contains the drug at an initial concentration, Co, no greater than the matrix saturation concentration
Reinforcing structure	Fabric or fibers are embedded in the matrix, generally toward the skin-distal side
Drug-compatible reinforcing portion	At least part of the reinforcement is a solvent for the drug
Differential release property	The reinforcing portion has lower drug solubility, Cr, than the matrix drug concentration, Co
Diffusion relationship	The reinforcing portion must satisfy DrCr < DmCo
Adhesion	Certain claims require peel strength sufficient for extended wear but low enough for comfortable removal
Thickness	Dependent claims specify 2 to 10 mils
Drug	Testosterone, progesterone and hydrocortisone are expressly recited in later claims
Application site	Scrotum or labia in method claims
Duration	Testosterone methods require at least about eight hours; some claims specify about 24 hours with replacement

The patent does not broadly claim every testosterone patch. A product must meet the claimed matrix, reinforcement, material, dimensional, adhesion, drug, and use limitations applicable to the asserted claim.

How does the drug-flux equation limit infringement?

The equation is the technical center of the patent:

[ D_r C_r < D_m C_o ]

Here:

Dm is the diffusion coefficient of the active agent in the primary matrix.
Dr is the diffusion coefficient in the solvent portion of the reinforcing structure.
Co is the initial drug concentration in the matrix.
Cr is the drug solubility in the reinforcing portion.

The claim requires the product of diffusion coefficient and concentration in the reinforcement to be lower than the corresponding product in the matrix. Claim 2 and related dependent claims impose a stricter requirement:

[ D_r C_r \leq 0.9D_m C_o ]

The specification’s design theory is that a low-flux reinforcing material can strengthen a thin patch without becoming the dominant diffusion barrier. A reinforcement that is chemically incompatible with the drug, or that creates a high drug-flux pathway, may fall outside the claimed relationship.

The equation creates several practical enforcement issues:

The accused product must be tested or modeled to establish Dm, Dr, Co and Cr.
The relevant solvent portion may be a fiber coating rather than the structural fiber core.
The claim does not require a particular absolute release rate. It requires a comparative relationship.
The relationship may vary by drug, polymer grade, temperature, hydration state and testing method.
Claims requiring the 10% differential are narrower than claim 1.

What is the scope of claims 1 through 20?

Claims 1 through 20 establish the principal platform architecture.

Claims 1 and 2: broad flux-differential system

Claim 1 is the broadest independent system claim. It requires:

A subsaturated drug-containing matrix.
Reinforcing means inside the matrix.
A reinforcing portion that is a drug solvent.
A lower drug-flux product in the reinforcement than in the matrix.

Claim 2 narrows the relationship by requiring the reinforcing flux capacity to be at least 10% lower.

These claims are not limited to testosterone. They can cover systems containing other active agents if the remaining limitations are satisfied.

Claims 3 and 4: fabric and thickness

Claim 3 specifies fabric embedded in the distal portion of the system. Claim 4 limits the overall thickness to approximately 2 to 10 mils.

“Distal” means the side away from the skin. The placement matters because the claimed reinforcement is not simply any support layer in any location. A reinforcement embedded in the skin-distal body of the matrix is a recurring limitation throughout the claim set.

Claims 5 through 7: sensitive-skin adhesion

These claims add:

Application to sensitive skin surfaces.
Extended wear.
Adhesion sufficient to maintain the patch.
Removal without discomfort.
Peel strength of 1 to 20 grams per centimeter.
A 2 to 10 mil overall thickness in claim 7.

The peel-strength limitation is material. A product with a different adhesion mechanism, or a product outside the stated peel-strength range, may avoid these dependent claims even if it has the claimed matrix and reinforcement.

Claims 8 through 10: testosterone and progesterone embodiments

Claim 8 narrows the system to:

Testosterone or progesterone.
An EVA matrix containing approximately 40% to 60% vinyl acetate.
A total thickness of approximately 2 to 10 mils.

Claims 9 and 10 claim application to the scrotum of a male subject or the labia of a female subject. These are method claims directed to transdermal administration rather than the patch structure alone.

Claims 11 through 20: fibrous reinforcement and coated fibers

Claims 11 and 12 specify fibrous reinforcement embedded in the skin-distal surface. Claims 13 and 14 require the drug-solvent portion to be a coating on the fibers.

Claim 20 is a second independent system claim. Compared with claim 1, it expressly combines:

A subsaturated matrix.
Fibrous reinforcement embedded in the body-distal surface.
An exterior fiber portion acting as the drug solvent.
The DrCr < DmCo relationship.
Adhesion suitable for sensitive skin and extended wear.

Claim 20 is structurally narrower than claim 1 but more focused on the patch configuration most relevant to thin, wearable systems.

What do claims 21 through 34 cover?

Claims 21 through 34 define specific material combinations.

Claim	Principal limitation
21	DrCr at least 10% less than DmCo
22	Overall thickness of 2 to 10 mils
23	Matrix selected from EVA, natural rubber, synthetic rubber or low-density polyethylene
24	Exterior reinforcing portion selected from polyolefins or polyarylamides
25	Progesterone, testosterone or hydrocortisone
26	EVA or styrene-butadiene block copolymer matrix with polyolefin or polyarylamide reinforcement
27	Claim 26 materials with progesterone, testosterone or hydrocortisone
28	EVA matrix with polyethylene exterior reinforcement
29	Styrene-butadiene block copolymer matrix with polyarylamide exterior reinforcement
30	Claim 28 combination with one of the specified agents
31	Claim 29 combination with one of the specified agents
32	Claim 30 with progesterone
33	Claim 30 with testosterone
34	Claim 31 with hydrocortisone

Claims 28 and 30 are particularly important for product comparison because they narrow the reinforcement to polyethylene and the matrix to EVA. Claim 33 then identifies testosterone as the active agent.

A testosterone patch using an EVA matrix and polyethylene-coated reinforcing fibers could be mapped directly against claims 28, 30 and 33, subject to the flux, thickness and other limitations. The patent’s expiration eliminates current infringement exposure, but this claim structure remains relevant to historical product analysis and freedom-to-operate reviews of continuation technology.

What do claims 35 through 43 cover?

Claims 35 through 43 focus on testosterone replacement.

Claims 35 and 36 specify testosterone in the claim 8 and claim 1 systems. Claims 37 and 38 cover applying the system to the scrotum of a hypogonadal male for at least about eight hours.

Claims 39 and 40 specify:

Approximately 24 hours of wear.
Removal and replacement with a fresh system.
Continuous testosterone replacement.

Claim 41 requires:

Testosterone.
An EVA matrix.
Approximately 40% to 60% vinyl acetate.

Claims 42 and 43 apply the eight-hour and 24-hour replacement method limitations to that embodiment.

The method claims are narrower than a product claim because they require a particular medical use and application site. A testosterone patch used on the abdomen, upper arm or back would not satisfy the scrotal-site limitation of claims 37 through 43, although it could raise separate issues under a broader system claim if the structural limitations were met.

When did U.S. Patent 4,704,282 expire?

U.S. Patent 4,704,282 expired in 2004.

Event	Date
Patent issued	November 3, 1987
Applicable term	17 years from issue for this pre-URAA patent
Statutory expiration	November 3, 2004
Current enforceability	None

The patent was issued before the 1995 patent-term transition. Under the applicable pre-URAA framework, the term was generally 17 years from grant, subject to any applicable terminal disclaimer, disclaimer, reexamination adjustment or other term event. Public patent records identify no current enforceable term for U.S. Patent 4,704,282. The patent is therefore prior art and historical IP, not a live exclusivity right. [1][2]

What was the FDA and Orange Book status of the related testosterone product?

The patent is associated with the development of ALZA’s Testoderm scrotal testosterone transdermal system. Testoderm was a small-molecule prescription product regulated through an NDA under section 505(b) of the Federal Food, Drug, and Cosmetic Act.

The relevant regulatory characteristics were:

Regulatory issue	Assessment
Active ingredient	Testosterone
Dosage form	Transdermal system
Product type	Small-molecule drug
FDA pathway	NDA, followed by potential ANDA generic competition
Biologic status	Not a biologic
Biosimilar pathway	Not applicable
Reference product	Testoderm, historically marketed testosterone transdermal system
Current patent barrier from 4,704,282	None
Current Orange Book significance	Historical unless an NDA remains listed and has active patents

Orange Book listings are tied to specific approved products and NDA holders. They do not create a complete record of every patent relevant to a transdermal delivery technology. A patent can be absent from the Orange Book because it claims manufacturing, formulation technology not required for approval, a discontinued product, or a technology outside the NDA holder’s listing practice. [3]

Were there Paragraph IV challenges to U.S. Patent 4,704,282?

No current Paragraph IV risk exists because the patent expired in 2004.

A Paragraph IV certification is relevant when an ANDA applicant asserts that a listed patent is invalid, unenforceable or not infringed before the patent’s expiration. For a patent that expired before the modern generic testosterone market developed, any historical certification would no longer create a present launch block.

The practical legal position is:

The patent could not support a new injunction against a generic product.
A current ANDA applicant would not need to challenge the expired patent to launch.
Any historical Paragraph IV dispute would have lost its commercial significance at expiration.
A later patent family, if separately listed and unexpired, would need independent analysis.

The claims’ technical specificity may have made a historical challenge fact-intensive. A Paragraph IV defense would likely focus on whether the generic system had the claimed reinforcement, whether the reinforcement was a solvent for testosterone, and whether the measured flux products satisfied the inequality.

Which later patents competed with this patent estate?

The main competitive landscape developed through later testosterone delivery products rather than continued enforcement of U.S. Patent 4,704,282.

Product or technology	Sponsor or developer	Delivery route	Patent relevance
Testoderm	ALZA and commercial partners	Scrotal transdermal patch	Closely aligned with the claimed scrotal patch architecture
Androderm	ALZA and later commercial owners	Non-scrotal transdermal patch	Associated with later testosterone patch patents, including U.S. Patent No. 5,152,997
AndroGel	Solvay and later AbbVie-related commercial owners	Topical gel	Relied on gel formulation and use patents rather than the claimed fiber-reinforced matrix
Testim	Auxilium and later Endo-related commercial owners	Topical gel	Competed through gel formulation and testosterone delivery technology
Axiron	Eli Lilly	Topical solution	Used a solution-based topical delivery system
Natesto	Trimel and later Acerus-related commercial owners	Nasal gel	Avoided the transdermal patch architecture
Generic testosterone gels and patches	Multiple ANDA sponsors	Topical or transdermal	Regulatory and formulation competition after product and patent exclusivities

U.S. Patent No. 5,152,997 is a later ALZA testosterone transdermal patent and is more relevant to later Androderm analysis than U.S. Patent 4,704,282. Its later expiration date illustrates the difference between the expired 1987 patent and subsequent patent protection. A product review must separate the two families rather than treating all ALZA testosterone patents as a single estate. [4][5]

How does this patent compare with later testosterone patent estates?

Issue	U.S. 4,704,282	Later testosterone patch patents	Testosterone gel patents
Primary technology	Reinforced polymer matrix	Later patch structures, reservoirs, adhesives or drug-release designs	Hydroalcoholic or other topical gels
Key technical limitation	Differential drug-flux capacity of matrix and reinforcement	Product-specific release, adhesive, backing or formulation limitations	Vehicle composition, permeation enhancers, dosing and application
Application site	Scrotum or labia in method claims	Often non-scrotal skin for later products	Shoulders, upper arms, abdomen or other labeled sites
Active ingredient	Testosterone among other agents	Testosterone-focused in later products	Testosterone
Patent status	Expired in 2004	Must be reviewed by patent number and product	Product-specific, with expiration dates varying by family
Biosimilar exposure	None	None	None
Generic pathway	505(j)	505(j), subject to active listed patents	505(j), subject to formulation and use patents

The 4,704,282 estate is technically narrower than a general transdermal testosterone concept. It is also broader than a single commercial patch because several claims cover non-testosterone agents and multiple matrix and reinforcement materials.

What manufacturing and IP barriers did the patent create?

The patent’s strongest practical barriers were manufacturing-specific:

Embedding reinforcement within a thin matrix without compromising drug release.
Applying or selecting a fiber coating that acts as a drug solvent.
Achieving the required diffusion and solubility relationship.
Maintaining a 2 to 10 mil thickness.
Controlling peel strength within the 1 to 20 gram-per-centimeter range where required.
Producing consistent testosterone loading across a thin patch.
Maintaining adhesion on sensitive, curved skin surfaces for eight to 24 hours.

These limitations could create process know-how barriers even where patent protection did not. After expiration, the technical barriers remained relevant to product development, but they no longer provided exclusivity.

How strong was the patent estate for U.S. Patent 4,704,282?

The patent had meaningful historical coverage of a specific transdermal platform but limited present commercial strength.

Strength factor	Assessment
Independent system claims	Stronger because claims 1 and 20 capture platform-level structure
Mathematical limitation	Potentially difficult to design around but testing-intensive to prove
Testosterone coverage	Direct and commercially relevant in claims 8, 15, 33, 35, 36 and 41
Method-of-use coverage	Narrow because several claims require scrotal application and hypogonadal males
Formulation coverage	Focused on EVA, rubber, polyethylene and related materials
Manufacturing coverage	Indirect; the claims cover the product structure rather than a detailed manufacturing process
Geographic coverage	United States only for this patent
Current enforceability	None after 2004
Biosimilar value	None; testosterone is a small molecule
Historical commercial value	High for the scrotal patch platform associated with Testoderm

The most commercially significant claims were likely those covering testosterone in an EVA matrix, a thin patch, and scrotal application. Claims 33, 37, 39, 41, 42 and 43 combine the technical system with the intended testosterone-replacement use.

What generic launch scenarios exist today?

A generic testosterone product is not blocked by U.S. Patent 4,704,282. Potential launch issues instead arise from:

Active Orange Book-listed patents for the specific reference product.
FDA requirements for therapeutic equivalence.
Product-specific bioequivalence or pharmacokinetic studies.
Adhesion and dose-delivery performance.
Labeling differences and method-of-use patents.
Manufacturing controls for thin polymer matrices.
Any remaining regulatory exclusivity, if applicable.

For a scrotal testosterone patch based on the expired architecture, the principal barriers would be development cost, FDA approval, clinical performance, manufacturing reproducibility and market size. The expired patent itself would not support an injunction or delay generic entry.

What patent litigation affects U.S. Patent 4,704,282?

No active patent litigation based on U.S. Patent 4,704,282 should affect current commercial planning because the patent expired nearly two decades ago.

Historical disputes involving testosterone patches may instead have concerned later patents, product labeling, generic substitution, or unrelated formulations. Patent litigation must be matched to the asserted patent number, NDA, product, defendant and filing date. References to “Testoderm patents” without separating U.S. Patent 4,704,282 from later ALZA patents can produce an inaccurate freedom-to-operate conclusion.

Key Takeaways

U.S. Patent 4,704,282 covers a reinforced, subsaturated transdermal matrix system.
The central limitation is the comparative flux equation DrCr < DmCo.
The claims cover fibrous or fabric reinforcement, drug-solvent coatings, thin 2 to 10 mil patches and controlled peel strength.
Testosterone, progesterone and hydrocortisone are expressly covered in dependent claims.
Claims 37 through 43 target testosterone replacement in hypogonadal males using scrotal application and eight- to 24-hour wear.
The patent issued on November 3, 1987 and expired in 2004.
It is not a current Orange Book or Paragraph IV barrier.
Testosterone is a small molecule, so biosimilar analysis is irrelevant.
Later patents, including U.S. Patent No. 5,152,997, must be analyzed separately.
Current generic risk turns on later product-specific patents, FDA requirements and manufacturing capability, not on U.S. Patent 4,704,282.

FAQs

Does U.S. Patent 4,704,282 cover all testosterone patches?

No. It covers testosterone patches only when the claimed matrix, reinforcement, flux relationship and other limitations are present.

Can a company sell a polyethylene-reinforced EVA testosterone patch today?

The patent does not prevent commercialization today because it expired in 2004. The product would still require FDA authorization and compliance with any later active patents.

Is the DrCr < DmCo equation a formulation patent limitation?

Yes. It is a product-structure limitation expressed through drug diffusion and solubility parameters in the matrix and reinforcing portion.

Did the patent cover non-scrotal testosterone delivery?

Some system claims are not limited to scrotal use. The specific testosterone replacement method claims in claims 37 through 43 require application to the scrotum.

Does this patent create freedom-to-operate risk for testosterone gel products?

No meaningful direct risk exists. Testosterone gels generally do not use the claimed fiber-reinforced matrix architecture, and the patent has expired.

References

United States Patent and Trademark Office. (1987). U.S. Patent No. 4,704,282, Transdermal therapeutic system.
United States Code, 35 U.S.C. § 154. Patent term and adjustment provisions.
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
United States Patent and Trademark Office. (1992). U.S. Patent No. 5,152,997, Testosterone transdermal therapeutic system.
U.S. Food and Drug Administration. (2009). Testoderm testosterone transdermal system prescribing information.

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Canada	1257819	⤷ Start Trial
Germany	3523065	⤷ Start Trial
Germany	3687067	⤷ Start Trial
European Patent Office	0232580	⤷ Start Trial
Spain	296615	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 4,704,282

Summary for Patent: 4,704,282